表紙
市場調査レポート

血液疾患向け薬剤および診断:世界市場

Drugs and Diagnostics for Hematological Disorders: Global Markets

発行 BCC Research 商品コード 263924
出版日 ページ情報 英文 429 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
血液疾患向け薬剤および診断:世界市場 Drugs and Diagnostics for Hematological Disorders: Global Markets
出版日: 2013年03月07日 ページ情報: 英文 429 Pages
概要

当レポートでは、世界の血液疾患向け治療薬および診断市場について調査し、市場の概要、世界市場の動向分析とCAGR予測、血液疾患・血液癌・血液診断別の市場分析、さまざまな白血病とその治療法のレビュー、FDA認可薬の説明、および主要企業のプロファイルなどをまとめ、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 血液疾患
  • 血液異常
  • ヘモグロビン異常
  • 止血
  • 出血性疾患
  • 血友病
  • 白血球異常
  • 血小板に影響する血液異常
  • 好酸球・異常
  • 好塩基球・異常
  • 形質細胞異常

第4章 血液癌

  • 典型的な分類
  • 急性骨髄性白血病
  • 慢性骨髄性白血病
  • 急性リンパ性白血病
  • 慢性リンパ球性白血病
  • ホジキンリンパ腫
  • 非ホジキンリンパ腫
  • 多発性骨髄腫
  • 骨髄異形成症候群

第5章 血液癌:白血病

  • リンパ性白血病
  • 骨髄性白血病
  • 血液癌向け薬剤治療
  • 結論

第6章 血液癌:リンパ腫

  • 概要
  • リンパ腫の原因
  • 分類

第7章 血液癌:骨髄腫

  • 概要
  • 骨髄腫の合併症
  • 骨髄腫の種類
  • 発生率
  • 診断
  • 病期
  • 結論

第8章 血液癌:骨髄異形成症候群

  • 分類
  • 国際予後スコアリングシステム
  • 診断・検査
  • 予後・治療選択肢
  • 化学療法
  • 対症療法
  • 薬剤プロファイル
  • 結論

第9章 血液癌:骨髄増殖性疾患

  • 慢性骨髄増殖性疾患の種類
  • 分類:WHO
  • 慢性骨髄増殖性疾患の病期
  • 真性赤血球増加症
  • 慢性特発性骨髄線維症
  • 本態性血小板血症
  • 慢性好中球性白血病
  • 慢性好酸球性白血病
  • サマリー

第10章 世界の発症率:血液疾患・血液癌

  • インド
  • ケニア
  • 世界の血液癌発症率
  • 出血性障害
  • 凝固障害

第11章 血液用器具類・試薬:世界市場の見通し

  • 血液系悪性腫瘍

第12章 血液疾患治療市場

  • 治療薬・市場

第13章 血液癌治療:市場

  • 概要

第14章 特許情勢・現在の発展

  • 血液癌治療薬:特許失効
  • 新規承認
  • 新しい血液癌治療薬
  • ニュース・発展
  • 開発中の薬剤
  • その他の発展
  • 血液疾患ニュース
  • 買収

第15章 主要企業のプロファイル

第16章 参考資料

図表リスト

目次
Product Code: PHM116A

Abstract

REPORT HIGHLIGHTS

This report provides:

An overview of the global market for drugs and diagnostics for hematological disorders.

Analyses of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017.

A breakdown of the market by hematological diseases, hematological cancers, and hematological diagnostics.

A review of blood cancers, such as various types of leukemia, lymphoma, and myeloma, and their therapies.

Delineation of drugs approved by the FDA for hematological disorders.

Comprehensive profiles of key companies in the industry.

image1

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This report "PHM116A Hematological Disorders: Drug Technologies, Diagnostics and Global Markets" provides an overview of the current and potential global market for hematological disorders, treatments and testing technologies. The key objective is to present a comprehensive analysis of the current state of hematological disorders and blood cancers, therapy and technology, and utilization of the various therapeutic and diagnostic modalities to prevent and treat these disorders. The report's focus is on hematological disorder treatment strategies such as hematological therapeutics and drugs, chemotherapy, radiotherapy and immunotherapy, and other treatment modalities and testing and screening methods. The report also includes an overview on hematological disorders and staging, diagnostic tests and technologies. Important trends in the field of hematological disorders and cancer research, new developments, and sales forecasts by treatment and screening categories from 2012 through 2017 are provided in this report. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the hematological disorders and blood cancer market.

REASONS FOR DOING THIS STUDY

This study was conducted to provide detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. There is an increasing need for new and innovative technologies. This industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer diagnostic and treatment strategies. Some of these ailments affect children and the elderly. This study looks at most types of diagnostic and treatment strategies for the clinical management of hematological disorders and blood cancers. This BCC market research report will increase the awareness of current and emerging drugs and technologies for hematological disorders and blood cancers, including hematological disorder therapeutics, chemotherapy, radiation therapy, surgical therapy, immunotherapy and also nutrition therapy.

INTENDED AUDIENCE

This report is an exhaustive study on the global hematological disorders and blood cancer market, with important statistics and analysis on existing drugs and diagnostic technologies, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in hematological disorders and blood cancer prevention and treatment strategies from the point of view of manufacturers, product suppliers, healthcare providers, and consumers of hematological disorder and cancer products and services. This study will be of interest largely to the pharmaceutical and biotechnology industries, as well as clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the concerned sector. This report shows tests currently being used for hematological disorders and cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. The report provides market data for 2010 to 2017 and also covers commercial prospects for hematological disorders and cancer diagnostic assays, current tests in use and their future.

SCOPE OF THE STUDY

The scope of this study is testing, screening technology and also therapeutics markets for hematological disorders and blood cancers. The report also includes the regulatory environment, current technologies, new technologies, hematological disorders and cancer incidence, market projections and market share, along with latest trends and new developments.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, industry news and developments, and paid and free databases. The base year of the report is 2012, with forecast data provided through 2017. Historical, base year and forecast data are provided for each market segment of this report. The report provides a comprehensive review of prostate cancer, incidence and development of the disease, drugs currently being used and diagnostic technologies. The report also reviews technological developments, product innovations/introductions and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth. Forecasts and projections were based on estimates such as the current trends, potential users, mergers and acquisitions, and market trends.

A comprehensive and exhaustive search of the literature on hematological disorders and blood cancers, assay development and already-marketed products, global incidence and latest drug developments was conducted. These secondary sources included scientific journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academics, technology and consulting companies.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products, such as the pharmaceutical and biotechnical industries and research institutes. Data were gathered from various industry sources. BCC spoke with officials within the industry and consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including IND enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.

Table of Contents

Chapter- 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC REPORTS
  • BCC ON-LINE SERVICES
  • DISCLAIMER

Chapter- 2: SUMMARY

  • Table Summary : HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, THROUGH 2017
  • Figure Summary : HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, 2010-2017

Chapter- 3: OVERVIEW

  • BLOOD DISEASES
  • BLOOD DISORDERS
  • HEMOGLOBIN DISORDERS
  • HEMOSTASIS
  • BLEEDING DISORDERS
  • HEMOPHILIA
  • WHITE BLOOD CELL DISORDERS
  • BLOOD DISORDERS AFFECTING PLATELETS
  • EOSINOPHILS AND DISORDERS
  • BASOPHILS AND DISORDERS
  • PLASMA CELL DISORDERS
  • Table 1 : KEY BLOOD DISORDERS
  • Table 2 : MALIGNANT BLOOD DISORDERS
  • Table 3 : NON-MALIGNANT BLOOD DISORDERS

Chapter- 4: HEMATOLOGICAL CANCERS

  • CLASSIC CLASSIFICATION
  • ACUTE MYELOID LEUKEMIA
  • CHRONIC MYELOID LEUKEMIA
  • ACUTE LYMPHOCYTIC LEUKEMIA
  • CHRONIC LYMPHOCYTIC LEUKEMIA
  • HODGKIN LYMPHOMA
  • NON-HODGKIN LYMPHOMA
  • MULTIPLE MYELOMA
  • MYELODYSPLASTIC SYNDROME
  • Table 35 : HEMATOLOGICAL CANCERS (BLOOD CANCERS)

Chapter- 5: HEMATOLOGICAL CANCERS: LEUKEMIA

  • LYMPHOCYTIC LEUKEMIAS
  • MYELOGENOUS LEUKEMIAS
  • DRUG THERAPIES FOR BLOOD CANCERS
  • CONCLUSIONS

Chapter- 6: HEMATOLOGICAL CANCERS: LYMPHOMA

  • OVERVIEW
  • LYMPHOMA CAUSES
  • CLASSIFICATION

Chapter- 7: HEMATOLOGICAL CANCERS: MYELOMA

  • OVERVIEW
  • COMPLICATIONS OF MYELOMA
  • TYPES OF MYELOMA
  • INCIDENCE
  • DIAGNOSIS
  • STAGING
  • CONCLUSIONS

Chapter- 8: HEMATOLOGICAL CANCER: MYELODYSPLASTIC SYNDROMES

  • CLASSES
  • INTERNATIONAL PROGNOSTIC SCORING SYSTEM
  • DIAGNOSIS AND TESTS
  • PROGNOSIS AND TREATMENT OPTIONS
  • CHEMOTHERAPY
  • SUPPORTIVE CARE
  • DRUG PROFILES
  • CONCLUSIONS
  • Table 84 : CHARACTERISTICS OF MDS
  • Table 85 : MDS CAUSES
  • Table 86 : MDS OR AML: THREE CATEGORIES

Chapter- 9: HEMATOLOGICAL CANCERS: MYELOPROLIFERATIVE DISORDERS

  • TYPES OF CHRONIC MYELOPROLIFERATIVE DISORDERS
  • CLASSIFICATION: WHO
  • STAGES OF CHRONIC MYELOPROLIFERATIVE DISORDERS
  • POLYCYTHEMIA VERA
  • CHRONIC IDIOPATHIC MYELOFIBROSIS
  • ESSENTIAL THROMBOCYTHEMIA
  • CHRONIC NEUTROPHILIC LEUKEMIA
  • CHRONIC EOSINOPHILIC LEUKEMIA
  • SUMMARY

Chapter- 10: WORLDWIDE INCIDENCE: BLOOD DISORDERS AND BLOOD CANCER

  • INDIA
  • KENYA
  • WORLDWIDE INCIDENCE OF BLOOD CANCER
  • BLOOD DISEASES AND INCIDENCE
  • BLEEDING DISORDERS
  • CLOTTING DISORDERS
  • Table 115 : CANCER KEY FACTS
  • Table 116 : INCREASE IN CANCER BURDEN: FACTORS

Chapter- 11: HEMATOLOGY INSTRUMENTS AND REAGENTS: A GLOBAL MARKET PERSPECTIVE

  • HEMATOLOGICAL MALIGNANCIES

Chapter- 12: BLOOD DISEASES TREATMENTS MARKET53$1,010

  • THERAPEUTIC DRUGS AND MARKET

Chapter- 13: HEMATOLOGICAL CANCER THERAPIES: MARKET

  • OVERVIEW

Chapter- 14: PATENT LANDSCAPE AND CURRENT DEVELOPMENTS

  • HEMATOLOGICAL CANCER DRUGS: PATENT EXPIRY
  • NEW APPROVALS
  • NEW HEMATOLOGICAL CANCER DRUGS
  • NEWS AND DEVELOPMENT
  • DRUGS IN DEVELOPMENT
  • OTHER DEVELOPMENTS
  • BLOOD DISORDERS NEWS
  • ACQUISATIONS
  • Table 281 : MAJOR DRUGS: PATENT EXPIRY
  • Table 282 : KEY DRUGS: PATENT EXPIRY
  • Table 283 : DRUGS LOSING PATENT PROTECTION BY 2015 AND THEIR GLOBAL SALES IN 2010

Chapter- 15: SELECTED COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ABON PHARMACEUTICALS
  • AMBIT BIOSCIENCES
  • AMGEN
  • AMPHASTAR PHARMACEUTICALS
  • ARIAD PHARMACEUTICALS
  • ASTELLAS PHARMA US
  • ASTRAZENECA
  • BAXTER HEALTHCARE CORPORATION
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOGEN IDEC
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB
  • C.R. BARD
  • CELGENE CORPORATION
  • CZ BIOMED CORP.
  • DECIPHERA PHARMACEUTICALS
  • DIAGNOCURE
  • EISAI INC.
  • ELI LILLY AND COMPANY
  • ENZON PHARMACEUTICALS
  • EXELIXIS
  • GE HEALTHCARE
  • GENMAB INC.
  • GILEAD SCIENCES
  • GLAXOSMITHKLINE
  • HOLOGIC
  • HORIBA LTD.
  • JOHNSON & JOHNSON
  • MEDKOO BIOSCIENCES
  • MOMENTA PHARMACEUTICALS
  • NOXXON PHARMA AG
  • OPKO HEALTH
  • PFIZER
  • PHARMACYCLICS
  • PORTOLA PHARMACEUTICALS INC.
  • ROCHE DIAGNOSTICS
  • SANOFI
  • SIEMENS AG
  • SPECTRUM PHARMACEUTICALS
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • THE MEDICINES COMPANY
  • WATSON PHARMACEUTICALS INC.
  • YM BIOSCIENCES INC.

Chapter- 16: REFERENCES

List of Tables

  • Summary Table : HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, THROUGH 2017
  • Table 1 : KEY BLOOD DISORDERS
  • Table 2 : MALIGNANT BLOOD DISORDERS
  • Table 3 : NON-MALIGNANT BLOOD DISORDERS
  • Table 4 : TYPE OF BLOOD CELLS AND FUNCTIONS
  • Table 5 : BLOOD CELLS AND FUNCTION
  • Table 6 : THREE MAJOR TYPES OF ANEMIA
  • Table 7 : ANEMIA: MAJOR CATEGORIES
  • Table 8 : SYMPTOMS OF ANEMIA
  • Table 9 : TYPES OF ANEMIA
  • Table 10 : DRUGS THAT CAN CAUSE COBALAMIN DEFICIENCY
  • Table 11 : DRUGS: CAUSE OF FOLATE DEFICIENCY
  • Table 12 : KEY FACTS
  • Table 13 : LAB TESTS FOR ANEMIA
  • Table 14 : HEMOSTASIS: THREE MAJOR STEPS
  • Table 15 : DRUGS THAT EFFECT ACTIVITY OF PLATELETS
  • Table 16 : ANTICOAGULANTS THAT ACT ON THROMBIN
  • Table 17 : BLEEDING DISORDERS
  • Table 18 : BLEEDING DISORDERS: SYMPTOMS
  • Table 19 : SIGNS AND TESTS
  • Table 20 : KEY CHARACTERISTICS: HEMOPHILIA
  • Table 21 : FVIII INHIBITORS
  • Table 22 : MEDICATIONS FOR TREATING HEMOPHILIA
  • Table 23 : FACTOR VIII PRODUCTS
  • Table 24 : ANTIFIBRINOLYTICS
  • Table 25 : ANTIHEMOPHILIC AGENTS
  • Table 26 : FORMATION OF THROMBUS
  • Table 27 : CAUSES FOR NEUTROPENIA
  • Table 28 : WHITE BLOOD CELLS AND DISEASES
  • Table 29 : CAUSE OF SECONDARY THROMBOCYTOSIS
  • Table 30 : DIAGNOSTIC TESTS
  • Table 31 : MEDICINES FOR THROMBOCYTHEMIA
  • Table 32 : CAUSES OF THROMBOCYTOPENIA
  • Table 33 : SIGNS OF EXTERNAL BLEEDING
  • Table 34 : COMMON DRUGS TO TREAT EOSINOPHILIA
  • Table 35 : HEMATOLOGICAL CANCERS (BLOOD CANCERS)
  • Table 36 : RELATIVE OCCURRENCE OF HEMATOLOGICAL MALIGNANCIES IN THE U.S.
  • Table 37 : TYPES OF HEMATOLOGICAL CANCERS
  • Table 38 : FDA APPROVED DRUGS FOR HEMATOLOGY, 2012
  • Table 39 : NEW HEMATOLOGY DRUG APPROVALS, 2012
  • Table 40 : FDA APPROVED DRUGS FOR HEMATOLOGY, 2011
  • Table 41 : APPROVED FDA DRUGS FOR HEMATOLOGICAL DISEASES, 1996-2010
  • Table 42 : TYPES OF LEUKEMIA
  • Table 43 : TYPES OF LEUKEMIA AND KEY FEATURES
  • Table 44 : DIAGNOSTIC EXAMS FOR LEUKEMIA
  • Table 45 : ADDITIONAL TESTS
  • Table 46 : PCR TESTS
  • Table 47 : NON-LABORATORY TESTS
  • Table 48 : COMMON TREATMENTS USED TO FIGHT LEUKEMIA
  • Table 49 : NEWER CLASSES OF DRUGS
  • Table 50 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) TREATMENT
  • Table 51 : DRUGS APPROVED FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
  • Table 52 : DRUGS APPROVED FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
  • Table 53 : DRUGS APPROVED FOR ACUTE MYELOID LEUKEMIA (AML)
  • Table 54 : DRUGS APPROVED FOR CHRONIC MYELOGENOUS LEUKEMIA (CML)
  • Table 55 : T-CELL PROLYMPHOCYTIC LEUKEMIA: TREATMENT PLAN
  • Table 56 : FACTORS AFFECTING LEUKEMIA STAGING AND PROGNOSIS
  • Table 57 : CHEMOTHERAPY DRUGS FOR CML
  • Table 58 : CHEMOTHERAPY DRUGS FOR CLL
  • Table 59 : TARGETED THERAPY DRUGS
  • Table 60 : ADVANTAGES OF RADIOIMMUNOTHERAPY
  • Table 61 : COMMON RADIATION TREATMENTS: LEUKEMIA
  • Table 62 : PAIN MEDICATIONS
  • Table 63 : EMERGING THERAPIES FOR LEUKEMIA
  • Table 64 : CAUSES FOR LYMPHOMA
  • Table 65 : LYMPHOMA TYPES
  • Table 66 : STAGING FOR HL AND NHL TUMORS
  • Table 67 : MATURE B-CELL NEOPLASMS
  • Table 68 : MATURE T-CELL AND NATURAL KILLER (NK) CELL NEOPLASMS
  • Table 69 : HODGKIN LYMPHOMA
  • Table 70 : IMMUNODEFICIENCY-ASSOCIATED LYMPHO- PROLIFERATIVE DISORDERS
  • Table 71 : SYMPTOMS OF LYMPHOMA
  • Table 72 : FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS
  • Table 73 : IMAGING TESTS
  • Table 74 : HL, THE INTERNATIONAL PROGNOSTIC INDEX
  • Table 75 : THE INTERNATIONAL PROGNOSTIC INDEX FOR NHL
  • Table 76 : PROMISING THERAPIES FOR TREATING LYMPHOMA
  • Table 77 : PROGNOSTIC INDICATORS FOR MYELOMA
  • Table 78 : OTHER BONE MARROW TESTS
  • Table 79 : MYELOMA: STAGING CRITERIA
  • Table 80 : MYELOMA'S RESPONSE TO TREATMENT
  • Table 81 : SUPPORTIVE CARE
  • Table 82 : DRUGS FOR MULTIPLE MYELOMA
  • Table 83 : EMERGING THERAPIES FOR MYELOMA
  • Table 84 : CHARACTERISTICS OF MDS
  • Table 85 : MDS CAUSES
  • Table 86 : MDS OR AML: THREE CATEGORIES
  • Table 87 : MYELODYSPLASTIC SYNDROMES: KEY FACTS
  • Table 88 : FAB CLASSIFICATION OF MDS
  • Table 89 : THE 2008 WHO CLASSIFICATION OF MDS
  • Table 90 : INTERNATIONAL PROGNOSTIC SCORING SYSTEM RISK GROUPS AND PROGNOSIS
  • Table 91 : CHANGES IN CELLS AND MDS
  • Table 92 : CHRONIC MYELOPROLIFERATIVE DISORDERS
  • Table 93 : CLASSIFICATION OF MYELOID NEOPLASMS ACCORDING TO THE 2008 WHO CLASSIFICATION SCHEME
  • Table 94 : MYELOPROLIFERATIVE NEOPLASMS: KEY FACTS
  • Table 95 : DIAGNOSTIC TESTS
  • Table 96 : SYMPTOMS OF POLYCYTHEMIA VERA
  • Table 97 : BLOOD TESTS FOR POLYCYTHEMIA VERA
  • Table 98 : TREATMENT FOR POLYCYTHEMIA VERA
  • Table 99 : CAUSATIVE FACTORS FOR MYELOFIBROSIS
  • Table 100 : COMPLICATIONS FROM MYELOFIBROSIS
  • Table 101 : WHO DIAGNOSTIC CRITERIA FOR PMF
  • Table 102 : RISK FACTORS
  • Table 103 : IDIOPATHIC MYELOFIBROSIS AND SYMPTOMS
  • Table 104 : PROGNOSIS
  • Table 105 : TREATMENT OF CHRONIC IDIOPATHIC MYELOFIBROSIS
  • Table 106 : SOMATIC MUTATIONS
  • Table 107 : CAUSES OF THROMBOCYTOSIS
  • Table 108 : SYMPTOMS
  • Table 109 : ESSENTIAL THROMBOCYTHEMIA: DIAGNOSTIC CRITERIA
  • Table 110 : TREATMENT OF ET
  • Table 111 : TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA
  • Table 112 : CHRONIC EOSINOPHILIC LEUKEMIA: SYMPTOMS
  • Table 113 : TREATMENT OF CHRONIC EOSINOPHILIC LEUKEMIA
  • Table 114 : CURRENT DRUGS
  • Table 115 : CANCER KEY FACTS
  • Table 116 : INCREASE IN CANCER BURDEN: FACTORS
  • Table 117 : CANCER CASES AND TREATMENT COST IN INDIA, 2008-2010
  • Table 118 : WORLDWIDE INCIDENCE OF BLOOD CANCER, 2008
  • Table 119 : WORLDWIDE INCIDENCE OF BLOOD CANCER IN MEN, 2008
  • Table 120 : WORLDWIDE INCIDENCE OF BLOOD CANCER IN WOMEN, 2008
  • Table 121 : TOP 10 COUNTRIES' CANCER RATES
  • Table 122 : ESTIMATED INCIDENCE RATES FOR BLOOD CANCERS IN THE U.S., 2010 AND 2011
  • Table 123 : ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2011
  • Table 124 : ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE IN THE U.S., 2012
  • Table 125 : GLOBAL INCIDENCE OF LEUKEMIA, 2010
  • Table 126 : LEUKEMIA INCIDENCE IN THE U.S.
  • Table 127 : ESTIMATED NEW CASES OF LEUKEMIA IN THE U.S., 2010-2012
  • Table 128 : ESTIMATED NEW CASES OF LEUKEMIA IN THE U.S., ADULTS AND CHILDREN, 2011
  • Table 129 : APPROXIMATE PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE U.S., 2008
  • Table 130 : LEUKEMIA IN ADULTS AND CHILDREN IN THE U.S., 2011
  • Table 131 : TYPES OF LEUKEMIA IN ADULTS IN THE U.S.
  • Table 132 : ESTIMATED LEUKEMIA INCIDENCE IN THE U.S., 2012
  • Table 133 : INCIDENCE RATES BY RACE, 2005-2009
  • Table 134 : THE FIVE-YEAR RELATIVE SURVIVAL RATES, 2001-2007
  • Table 135 : ESTIMATED DEATHS FOR LEUKEMIA IN THE U.S., 2011
  • Table 136 : LEUKEMIA STATISTICS IN THE U.K.: NUMBER OF NEW CASES, INCIDENCE RATES BY GENDER PER 100,000 POPULATION, 2008
  • Table 137 : ACS ESTIMATES FOR ACUTE LYMPHOCYTIC LEUKEMIA (ALL) INCIDENCE IN THE U.S., 2012
  • Table 138 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: WORLDWIDE, 2008
  • Table 139 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: WORLDWIDE, 2008
  • Table 140 : HODGKIN LYMPHOMA WORLDWIDE, 2008
  • Table 141 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: EU-27 COUNTRIES, 2008
  • Table 142 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: EU-27 COUNTRIES, 2008
  • Table 143 : HODGKIN LYMPHOMA IN EU-27 COUNTRIES, 2008
  • Table 144 : ESTIMATED NEW CASES AND DEATHS FOR LYMPHOMA IN THE U.S., 2012
  • Table 145 : ESTIMATED NEW CASES AND DEATHS OF LYMPHOMA IN THE U.S., 2011 AND 2012
  • Table 146 : ESTIMATED NEW CASES OF LYMPHOMA TYPES IN THE U.S., 2011 AND 2012
  • Table 147 : NEW CASES OF LYMPHOMA BY GENDER, 2011
  • Table 148 : ESTIMATED DEATHS FROM LYMPHOMA BY GENDER, 2011
  • Table 149 : AGE-SPECIFIC INCIDENCE RATES, BY GENDER, FOR NHL
  • Table 150 : INCIDENCE RATES BY RACE, 2005-2009
  • Table 151 : DEATH RATES BY RACE, 2005-2009
  • Table 152 : STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, 2002-2008
  • Table 153 : NON-HODGKIN LYMPHOMA IN THE U.K.: NUMBER OF NEW CASES, INCIDENCE, 2009
  • Table 154 : NON-HODGKIN LYMPHOMA DEATH IN THE U.K. MORTALITY, 2010
  • Table 155 : ESTIMATED HODGKIN LYMPHOMA STATISTICS IN THE U.K., 2008
  • Table 156 : HODGKIN'S LYMPHOMA IN THE U.K., 2008
  • Table 157 : MYELOMA INCIDENCE WORLDWIDE, 2008
  • Table 158 : MYELOMA MORTALITY RATES WORLD WIDE, 2008
  • Table 159 : MYELOMA INCIDENCE RATES, EU-27 COUNTRIES, 2008
  • Table 160 : MYELOMA MORTALITY RATES WORLD WIDE, 2008
  • Table 161 : ESTIMATED INCIDENCE AND DEATHS FOR MYELOMA IN THE U.S., 2011 AND 2012
  • Table 162 : ESTIMATED INCIDENCE OF MYELOMA IN THE U.S. BY GENDER, 2011 AND 2012
  • Table 163 : INCIDENCE RATES BY RACE AND GENDER, 2005-2009
  • Table 164 : DEATH RATES BY RACE AND GENDER, 2005-2009
  • Table 165 : DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, 2002-2008
  • Table 166 : MYELOMA STATISTICS IN THE U.K. NUMBER OF NEW CASES: INCIDENCE RATES PER 100,000 POPULATION, 2009
  • Table 167 : MYELOMA NUMBER OF DEATHS IN THE U.K. MORTALITY RATES PER 100,000 POPULATION, 2010
  • Table 168 : ESTIMATED NEW CASES FOR MDS IN THE U.S., 2012
  • Table 169 : GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, THROUGH 2017
  • Table 170 : KEY PRODUCTS
  • Table 171 : GLOBAL MAJOR PLAYERS IN THE HEMATOLOGY MARKET
  • Table 172 : FLOW CYTOMETRY 171: KEY PLAYERS
  • Table 173 : FLOW CYTOMETRY PRODUCTS: SALES AND FORECAST, THROUGH 2017
  • Table 174 : MAJOR FLOW CYTOMETRY APPLICATIONS
  • Table 175 : CELL ANALYZERS: KEY PLAYERS
  • Table 176 : HEMATOLOGY TESTS
  • Table 177 : COMPLETE BLOOD COUNT: COMPONENTS MEASURED
  • Table 178 : TESTS INCLUDED IN A CHEMISTRY SCREEN
  • Table 179 : CHEMISTRY SCREEN
  • Table 180 : URINE TESTS AND APPLICATIONS
  • Table 181 : IVD PRODUCTS MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 182 : UNITED STATES: IVD MARKET SALES AND FORECAST, THROUGH 2017
  • Table 183 : GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS: SALES AND FORECAST, THROUGH 2017
  • Table 184 : GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS: SALES AND FORECAST, THROUGH 2017
  • Table 185 : KEY PLAYERS IN THE IMMUNOASSAYS MARKET
  • Table 186 : MOLECULAR DIAGNOSTICS MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 187 : MAJOR PLAYERS: MOLECULAR DIAGNOSTICS MARKET
  • Table 188 : THE POINT-OF-CARE (POC) TESTING MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 189 : GLOBAL MARKET FOR POC TESTS: SALES AND FORECAST, THROUGH 2017
  • Table 190 : THE POINT-OF-CARE IMMUNOASSAY MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 191 : MARKET PLAYERS
  • Table 192 : GLOBAL BLOOD DISORDER MARKET, THROUGH 2017
  • Table 193 : GLOBAL BLOOD DISORDER MARKET SHARE, 2010 AND 2017
  • Table 194 : PATENT EXPIRIES OF MAJOR BLOCKBUSTERS
  • Table 195 : KEY PLAYERS: PRODUCTS AND MARKET SHARE, 2010
  • Table 196 : MARKET DRIVERS
  • Table 197 : MARKET RESTRAINTS
  • Table 198 : ANEMIA TREATMENT MARKET, THROUGH 2017
  • Table 199 : ERYTHROPOIETIN STIMULATING AGENTS (ESAS)
  • Table 200 : KEY ANEMIA DRUGS SALES, 2010-2012
  • Table 201 : NEORECORMON/EPOGIN SALES AND FORECAST, 2010-2012
  • Table 202 : GLOBAL NEORECORMON/EPOGIN SALES, 2009
  • Table 203 : COMMON ANEMIA TREATMENTS
  • Table 204 : AKEBIA THERAPEUTICS ANEMIA DRUG IN DEVELOPMENT-AKB-6548
  • Table 205 : GLOBAL THROMBOSIS THERAPEUTIC MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 206 : LEADING DRUGS IN THE ANTITHROMBOTIC AGENTS MARKET
  • Table 207 : GLOBAL ANTICOAGULANT DRUG MARKET SALES AND FORECAST, THROUGH 2017
  • Table 208 : GLOBAL ANTIPLATELET DRUG MARKET, THROUGH 2017
  • Table 209 : ANTIPLATELET AND ANTICOAGULANT DRUGS
  • Table 210 : ANTIPLATELET DRUGS (PLATELET ADP ANTAGONISTS): SALES AND FORECAST, THROUGH 2017
  • Table 211 : U.S. SALES: PLAVIX, 2012
  • Table 212 : GLOBAL SEMULOPARIN SALES AND FORECAST, THROUGH 2017
  • Table 213 : ANTITHROMBOTIC AGENTS (BY PHARMACOLOGICAL CLASS): SALES AND FORECAST, 2010-2017
  • Table 214 : XARELTO: APPROVALS IN VENOUS ARTERIAL THROMBOEMBOLIC (VAT) INDICATIONS
  • Table 215 : ANTITHROMBOTIC AGENTS IN DEVELOPMENT
  • Table 216 : ACTIVASE: SALES AND FORECAST, THROUGH 2017
  • Table 217 : ANGIOMAX: SALES AND FORECAST, 2010-2017
  • Table 218 : KEY PLATELET AGGREGATION INHIBITOR DRUG SALES AND FORECAST, 2010-2017
  • Table 219 : PLATELET AGGREGATION INHIBITORS: PIPELINE DRUGS
  • Table 220 : PLATELET INHIBITOR: PIPELINE DRUGS
  • Table 221 : THROMBOSIS MARKET: PIPELINE DRUGS
  • Table 222 : GLOBAL NEUTROPENIA DRUG MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 223 : KEY DRUGS
  • Table 224 : GROWTH FACTORS FOR TREATING NEUTROPENIA
  • Table 225 : WORLDWIDE SALES OF NEULASTA/NEUPOGEN, 2010-2012
  • Table 226 : SARGRAMOSTIM SALES, 2010
  • Table 227 : COMPANIES IN EUROPE WITH SHORT-ACTING FILGRASTIMS IN PHASE 3 CLINICAL DEVELOPMENT
  • Table 228 : HEMOPHILIA A THERAPEUTICS MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 229 : KEY PLAYERS IN THE HEMOPHILIA A THERAPEUTICS MARKET
  • Table 230 : KEY HEMOPHILIA DRUGS
  • Table 231 : GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, 2010
  • Table 232 : GLOBAL BLOOD DISORDERS PIPELINE MOLECULES
  • Table 233 : CYTOTOXIC THERAPIES MARKET INDICATIONS
  • Table 234 : LIST OF LEUKEMIA MEDICATIONS
  • Table 235 : GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017
  • Table 236 : U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2017
  • Table 237 : EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2017
  • Table 238 : JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2017
  • Table 239 : MAJOR PLAYERS IN THE LEUKEMIA MARKET
  • Table 240 : LEUKEMIA: CATEGORIES
  • Table 241 : GLOBAL LEUKEMIA MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 242 : U.S. LEUKEMIA MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 243 : EUROPEAN LEUKEMIA MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 244 : JAPAN'S LEUKEMIA MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 245 : GLOBAL LEUKEMIA MARKET BY GEOGRAPHICAL REGIONS: SALES AND FORECAST, THROUGH 2017
  • Table 246 : LEUKEMIA MARKET SHARE FORECAST, 2011-2017
  • Table 247 : CHRONIC MYELOGENOUS LEUKEMIA (CML) MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 248 : DRUG CLASSES FOR LEUKEMIA DRUG DEVELOPMENT
  • Table 249 : KEY CHRONIC MYELOGENOUS LEUKEMIA (CML) SALES AND FORECAST, 2010-2012
  • Table 250 : KEY CML MEDICINES AND COST
  • Table 251 : GLEEVAC: FDA APPROVALS
  • Table 252 : PIPELINE DRUGS FOR LEUKEMIA
  • Table 253 : ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, THROUGH 2017
  • Table 254 : MAJOR PLAYERS IN THE ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET
  • Table 255 : DRUGS FOR ALL TREATMENT
  • Table 256 : APPROVED DRUGS FOR ALL
  • Table 257 : GLOBAL ACUTE MYELOID LEUKEMIA MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 258 : KEY COMPANIES IN THE AML MARKET
  • Table 259 : CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 260 : ARZERRA: SALES AND FORECAST, 2010-2017
  • Table 261 : TREANDA SALES, THROUGH 2017
  • Table 262 : KEY PLAYERS IN THE CLL MARKET
  • Table 263 : TREATMENT GENERIC DRUGS USED IN COMBINATION FOR HODGKIN LYMPHOMA
  • Table 264 : TREATMENT DRUGS USED IN COMBINATION FOR NON-HODGKIN LYMPHOMA
  • Table 265 : NON-HODGKIN'S LYMPHOMA DRUG MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 266 : RITUXIMAB SALES AND FORECAST, 2010-2012
  • Table 267 : RITUXAN: BIOSIMILARS IN DEVELOPMENT
  • Table 268 : REVLIMID SALES AND FORECAST, 2011 AND 2012
  • Table 269 : HODGKIN'S LYMPHOMA TREATMENT MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 270 : MULTIPLE MYELOMA TREATMENT MARKET: SALES AND FORECAST, THROUGH 2017
  • Table 271 : DRUGS FOR THE MYELOMA MARKET
  • Table 272 : DRUGS IN DEVELOPMENT
  • Table 273 : TREANDA CLINICAL TRIALS IN RELAPSED AND/OR REFRACTORY MYELOMA
  • Table 274 : MARKET FOR MYELODYSPLASTIC SYNDROME, THROUGH 2017
  • Table 275 : APPROVED DRUGS FOR THE TREATMENT OF MDS
  • Table 276 : MARKET FOR MYELOPROLIFERATIVE DISORDERS, THROUGH 2017
  • Table 277 : JAK2 INHIBITORS IN DEVELOPMENT
  • Table 278 : RUXOLITINIB FORECAST, 2012 AND 2017
  • Table 279 : MARKET FOR MYELOFIBROSIS, THROUGH 2017
  • Table 280 : MARKET FOR POLYCYTHEMIA VERA, THROUGH 2017
  • Table 281 : MAJOR DRUGS: PATENT EXPIRY
  • Table 282 : KEY DRUGS: PATENT EXPIRY
  • Table 283 : DRUGS LOSING PATENT PROTECTION BY 2015 AND THEIR GLOBAL SALES IN 2010
  • Table 284 : BIOLOGICS: PATENT EXPIRY
  • Table 285 : NEW DRUG APRROVALS FOR BLOOD DISORDERS, 2012
  • Table 286 : NEW DRUG APRROVALS FOR HEMATOLOGICAL CANCERS, 2012

List of Figures

  • Summary Figure : HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, 2010-2017
  • Figure 1 : ESTIMATED INCIDENCE RATES FOR BLOOD CANCERS IN THE U.S., 2010 AND 2011
  • Figure 2 : ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2011
  • Figure 3 : ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE IN THE U.S., 2012
  • Figure 4 : ESTIMATED NEW CASES OF LEUKEMIA IN THE U.S., 2010-2012
  • Figure 5 : APPROXIMATE PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE UNITED STATES, 2008
  • Figure 6 : LEUKEMIA IN ADULTS AND CHILDREN IN THE U.S., 2011
  • Figure 7 : ESTIMATED LEUKEMIA INCIDENCE IN THE U.S., 2012
  • Figure 8 : ESTIMATED DEATHS FOR LEUKEMIA IN THE U.S., 2011
  • Figure 9 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: WORLDWIDE, 2008
  • Figure 10 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: WORLDWIDE, 2008
  • Figure 11 : HODGKIN LYMPHOMA WORLDWIDE, 2008
  • Figure 12 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: EU-27 COUNTRIES, 2008
  • Figure 13 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: EU-27 COUNTRIES, 2008
  • Figure 14 : HODGKIN LYMPHOMA IN EU-27 COUNTRIES, 2008
  • Figure 15 : ESTIMATED NEW CASES AND DEATHS FOR LYMPHOMA IN THE U.S., 2012
  • Figure 16 : ESTIMATED NEW CASES AND DEATHS OF LYMPHOMA IN THE U.S., 2011 AND 2012
  • Figure 17 : ESTIMATED NEW CASES OF LYMPHOMA TYPES IN THE U.S., 2011 AND 2012
  • Figure 18 : NEW CASES OF LYMPHOMA BY GENDER, 2011
  • Figure 19 : ESTIMATED DEATHS FROM LYMPHOMA BY GENDER, 2011
  • Figure 20 : HODGKIN'S LYMPHOMA IN THE U.K., 2008
  • Figure 21 : MYELOMA INCIDENCE WORLDWIDE, 2008
  • Figure 22 : MYELOMA MORTALITY RATES WORLD WIDE, 2008
  • Figure 23 : MYELOMA INCIDENCE RATES, EU-27 COUNTRIES, 2008
  • Figure 24 : MYELOMA MORTALITY RATES, WORLDWIDE, 2008
  • Figure 25 : ESTIMATED INCIDENCE AND DEATHS FOR MYELOMA IN THE U.S., 2011 AND 2012
  • Figure 26 : ESTIMATED INCIDENCE OF MYELOMA IN THE U.S. BY GENDER, 2011 AND 2012
  • Figure 27 : GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, 2010-2017
  • Figure 28 : FLOW CYTOMETRY PRODUCTS: SALES AND FORECAST, 2010-2017
  • Figure 29 : IVD PRODUCTS MARKET: SALES AND FORECAST, 2010-2017
  • Figure 30 : UNITED STATES: IVD MARKET SALES AND FORECAST, 2010-2017
  • Figure 31 : GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS: SALES AND FORECAST, 2010-2017
  • Figure 32 : GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS: SALES AND FORECAST, 2010-2017
  • Figure 33 : MOLECULAR DIAGNOSTICS MARKET: SALES AND FORECAST, 2010-2017
  • Figure 34 : THE POINT-OF-CARE (POC) TESTING MARKET: SALES AND FORECAST, 2010-2017
  • Figure 35 : GLOBAL MARKET FOR POC TESTS: SALES AND FORECAST, 2012 AND 2017
  • Figure 36 : THE POINT-OF-CARE IMMUNOASSAY MARKET: SALES AND FORECAST, 2012 AND 2017
  • Figure 37 : GLOBAL BLOOD DISORDER MARKET, 2010-2017
  • Figure 38 : ANEMIA TREATMENT MARKET, 2010-2017
  • Figure 39 : KEY ANEMIA DRUGS SALES, 2010-2012
  • Figure 40 : NEORECORMON/EPOGIN SALES AND FORECAST, 2010-2012
  • Figure 41 : GLOBAL THROMBOSIS THERAPEUTIC MARKET: SALES AND FORECAST, 2010-2017
  • Figure 42 : GLOBAL ANTICOAGULANT DRUG MARKET SALES AND FORECAST, 2010-2017
  • Figure 43 : GLOBAL ANTIPLATELET DRUG MARKET, 2010-2017
  • Figure 44 : GLOBAL SEMULOPARIN SALES AND FORECAST, 2011-2017
  • Figure 45 : GLOBAL NEUTROPENIA DRUG MARKET: SALES AND FORECAST, 2010-2017
  • Figure 46 : HEMOPHILIA A THERAPEUTICS MARKET: SALES AND FORECAST, 2010-2017
  • Figure 47 : GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, 2010
  • Figure 48 : GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017
  • Figure 49 : U.S. CYTOTHERAPEUTICS MARKET, 2010-2017
  • Figure 50 : EUROPEAN CYTOTHERAPEUTICS MARKET, 2010-2017
  • Figure 51 : JAPANESE CYTOTHERAPEUTICS MARKET, 2010-2017
  • Figure 52 : GLOBAL LEUKEMIA MARKET: SALES AND FORECAST, 2010-2017
  • Figure 53 : U.S. LEUKEMIA MARKET: SALES AND FORECAST, 2010-2017
  • Figure 54 : EUROPEAN LEUKEMIA MARKET: SALES AND FORECAST, 2010-2017
  • Figure 55 : JAPAN'S LEUKEMIA MARKET: SALES AND FORECAST, 2010-2017
  • Figure 56 : GLOBAL LEUKEMIA MARKET BY GEOGRAPHICAL REGIONS: SALES AND FORECAST, 2010-2017
  • Figure 57 : CHRONIC MYELOGENOUS LEUKEMIA (CML) MARKET: SALES AND FORECAST, 2010-2017
  • Figure 58 : KEY CHRONIC MYELOGENOUS LEUKEMIA (CML) SALES AND FORECAST, 2010-2012
  • Figure 59 : ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, 2010-2017
  • Figure 60 : GLOBAL ACUTE MYELOID LEUKEMIA MARKET: SALES AND FORECAST, 2010-2017
  • Figure 61 : CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) MARKET: SALES AND FORECAST, 2010-2017
  • Figure 62 : NON-HODGKIN'S LYMPHOMA DRUG MARKET: SALES AND FORECAST, 2010-2017
  • Figure 63 : HODGKIN'S LYMPHOMA TREATMENT MARKET: SALES AND FORECAST, 2010-2017
  • Figure 64 : MULTIPLE MYELOMA TREATMENT MARKET: SALES AND FORECAST, 2010-2017
  • Figure 65 : MARKET FOR MYELODYSPLASTIC SYNDROME, 2010-2017
  • Figure 66 : MARKET FOR MYELOPROLIFERATIVE DISORDERS, 2010-2017
  • Figure 67 : MARKET FOR MYELOFIBROSIS, 2010-2017
  • Figure 68 : MARKET FOR POLYCYTHEMIA VERA, 2010-2017
Back to Top